Clinical Trial

A First-in-human Study of KT501 Administered Subcutaneously to Patients With Rheumatoid Arthritis (RA).

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1, open-label, first-in-human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of KT501 administered subcutaneously to participants with Rheumatoid Arthritis (RA).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-14.
Status change: Not Yet Recruiting → Recruiting 2026-03-06
Trial Details
NCT Number NCT07234773
Lead Sponsor Kali Therapeutics, Inc.
Conditions Rheumatoid Arthritis (RA)
Enrollment 24 participants
Start Date 2026-03-06
Primary Completion 2027-02 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-03-10